Exane Asset Management Dbv Technologies S.A. Transaction History

Exane Asset Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 24, 2019	SELL	$8.57 - $10.72 $1.63 Million - $2.04 Million	-190,000 Closed	0 $0
Q2 2019 Aug 05, 2019	SELL	$7.58 - $10.0 $113,700 - $150,000	-15,000 Reduced 7.32%	190,000 $0
Q1 2019 May 07, 2019	BUY	$5.81 - $9.37 $377,650 - $609,050	65,000 Added 46.43%	205,000 $0
Q4 2018 Feb 05, 2019	BUY	$5.75 - $21.85 $431,250 - $1.64 Million	75,000 Added 115.38%	140,000 $898,000
Q3 2018 Nov 16, 2018	BUY	$16.81 - $24.58 $252,149 - $368,700	15,000 Added 30.0%	65,000 $0

Q2 2018 Sep 06, 2018	BUY	$18.6 - $24.94 $141,360 - $189,544	7,600 Added 17.92%	50,000 $0
Q1 2018 Apr 30, 2018	SELL	$20.86 - $26.6 $1.62 Million - $2.06 Million	-77,600 Reduced 64.67%	42,400 $0
Q4 2017 Feb 08, 2018	SELL	$20.9 - $49.36 $480,699 - $1.14 Million	-23,000 Reduced 16.08%	120,000 $0
Q3 2017 Oct 13, 2017	BUY	$39.62 - $46.17 $5.67 Million - $6.6 Million	143,000	143,000 $6.07 Billion

37.7M

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $146M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

Stay updated on Exane Asset Management with notifications on news.